Supernus Pharmaceuticals, Inc.
Company Overview
Overall Headcount Trend
Overall Headcount Trend
Company growth over the last 12 months
Hiring Activity
Open Marketing Jobs Over Time
Historical trend of active job postings
Salaries
Job Posting Salary Data
From 1 marketing roles posted in the last 12 months
Community Salary Data
Help build salary transparency at Supernus Pharmaceuticals, Inc.. Share your compensation anonymously.
Reviews
Share Interview Experience
Help others prepare by sharing your interview process, questions asked, and tips.
Rate This Company
Share your experience working here including compensation, culture, and work-life balance.
Founders
Marketing Leadership
Hiring Contacts
News
Jobs
About Supernus Pharmaceuticals, Inc.
We are a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our extensive expertise in product development has been built over the past 30 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, in late 2005, as Supernus Pharmaceuticals Inc. We market our products in the United States through our own specialty sales force and seek strategic collaborations with other pharmaceutical companies to license our products outside the United States.We market Qelbree® (viloxazine extended-release) for the treatment of attention deficit/hyperactivity disorder (ADHD) in children ages 6 to 17. Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy, Apokyn® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD), Myobloc® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults, and Xadago® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility.We are also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD in adults, apomorphine infusion pump for hypomobility in PD, SPN-820 (NV-5138) for treatment-resistant depression, and SPN-817 for the treatment of epilepsy.
Company Information
- Company Type
- In-House Team
- Company Size
- Founded
- 2005
- Headquarters
- Rockville
Why Work at Supernus Pharmaceuticals, Inc.?
Discover what makes Supernus Pharmaceuticals, Inc. a great place to build your marketing career. View salary data, benefits, and employee insights on the other tabs.
